Get the Stockscreener App
5.41
0.73%
-0.04
Pre-market:
5.44
0.03
+0.55%
Protara Therapeutics Inc stock is traded at $5.41, with a volume of 471.38K.
It is down -0.73% in the last 24 hours and up +5.87% over the past month.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
See More
Previous Close:
$5.45
Open:
$5.53
24h Volume:
471.38K
Relative Volume:
0.53
Market Cap:
$297.88M
Revenue:
-
Net Income/Loss:
$-57.44M
P/E Ratio:
-4.0491
EPS:
-1.3361
Net Cash Flow:
$-56.46M
1W Performance:
+6.92%
1M Performance:
+5.87%
6M Performance:
+21.85%
1Y Performance:
+59.59%
1-Day Range:
$5.36
$5.64
1-Week Range:
$4.95
$5.64
52-Week Range:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.41 | 297.88M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | JP Morgan | Overweight |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Will New Bladder Cancer Data Revive Protara's Momentum? - RTTNews
One Protara Therapeutics Insider Raised Their Stake In The Previous Year - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Raises Target Price to $27 - Moomoo
TARA Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
[ARS] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara Therapeutics (TARA) seeks more shares, officer protections in 2026 vote - Stock Titan
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada
BlackRock (TARA) reports 3,387,459 shares, 6.3% stake (Schedule 13G) - Stock Titan
Bladder cancer trial update from 31 patients goes to urology meeting - Stock Titan
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Protara announces proposed public offering - MSN
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TARA (NASDAQ: TARA) files Form 144 listing multiple proposed share sales - Stock Titan
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Protara Therapeutics (TARA) Market Position | Q4 2025: EPS Misses ViewsWall Street Picks - Cổng thông tin điện tử Tỉnh Sơn La
Protara Therapeutics Inc stock (US87612E1064): Is its rare disease pipeline strong enough to drive i - AD HOC NEWS
Protara Therapeutics (NASDAQ: TARA) seeks approval to double authorized shares to 200M - Stock Titan
Protara's experimental bladder cancer drug shows encouraging results - MSN
Protara Therapeutics Inc stock (US87612E1064): Is its rare disease pipeline strong enough to unlock - AD HOC NEWS
Published on: 2026-04-14 02:30:36 - baoquankhu1.vn
Exit Recap: Can Protara Therapeutics Inc beat the S P 5002026 Institutional & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Retail Trends: Can Protara Therapeutics Inc beat the S P 5002026 Institutional Moves & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Upgrade: Will Protara Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock - Investing.com Australia
Insider Sell: Jacqueline Zummo Sells Shares of Protara Therapeutics Inc (TARA) - GuruFocus
Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) R&D chief sells 1,134 shares under 10b5-1 plan - Stock Titan
Is Protara Therapeutics (TARA) Stock Underperforming | Price at $5.17, Down 0.98%Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Quarterly Risk: Is Protara Therapeutics Inc trading at a discountBuy Signal & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Stock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA) - MarketBeat
Sentiment Review: Whats Protara Therapeutics Incs historical returnWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Investor Mood: Can Protara Therapeutics Inc deliver consistent EPS growth2026 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
TARA Stock Analysis: Protara Therapeutics biotech posts 1.39 percent gain at 5.11 dollar level - Cổng thông tin điện tử tỉnh Lào Cai
Insider Sell: Jacqueline Zummo Sells 22,598 Shares of Protara Th - GuruFocus
Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock - MarketBeat
Protara (TARA) Chief R&D Officer sells 22,598 shares under 10b5-1 plan - Stock Titan
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
TARA Stock Analysis: Protara Therapeutics Inc. 0.96% Daily Dip Near $5.16 Trend Review - Xã Thanh Hà
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Risk Hedge: What is the target price for Protara Therapeutics Inc stock2026 Trading Recap & Momentum Based Trading Ideas - baoquankhu1.vn
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results - TipRanks
Protara Therapeutics reports six-month response rate in bladder cancer trial - Investing.com
Protara Therapeutics reports six-month response rate in bladder cancer trial By Investing.com - Investing.com South Africa
Protara reports 68.0% six-month CR rate in 25 BCG-unresponsive patients, warrants exercisable through June 29, 2026 - TradingView
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):